TY - JOUR T1 - Review: cholinesterase inhibitors may be effective in Alzheimer’s disease JF - Evidence Based Medicine JO - Evid Based Med SP - 23 LP - 23 DO - 10.1136/ebm.11.1.23 VL - 11 IS - 1 A2 - , Y1 - 2006/02/01 UR - http://ebm.bmj.com/content/11/1/23.abstract N2 - Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ 2005;331:321–7.OpenUrlAbstract/FREE Full Text 
 
 Q In patients with Alzheimer’s disease (AD), does treatment with cholinesterase inhibitors (donepezil, rivastigmine, or galantamine) improve clinical outcomes? Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Geriatrics ★★★★★★★ Psychiatry ★★★★★★☆ Neurology ★★★★★★☆ Data sources: Medline (1989 to November 2004), EMBASE/Excerpta Medica (1989 to November 2004), the Cochrane Database of Systematic Reviews, and bibliographies of relevant studies. Study selection and assessment: randomised controlled trials (RCTs) (published in any language) that compared cholinesterase inhibitors (donepezil, rivastigmine, or galantamine) with placebo in patients with AD. Studies that did not examine clinical outcomes or focused on vascular dementia were excluded. Outcomes: measures of clinical outcome included Alzheimer’s Disease Assessment-Cognitive Subscale, Clinician’s Interview-Based Impression … ER -